Literature DB >> 18214558

Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

M E Falagas1, M D Kanellopoulou, D E Karageorgopoulos, G Dimopoulos, P I Rafailidis, N D Skarmoutsou, E A Papafrangas.   

Abstract

We evaluated the antimicrobial activity of fosfomycin against a randomly selected sample of 30 Klebsiella pneumoniae, 30 Pseudomonas aeruginosa, and 30 Acinetobacter baumannii multidrug-resistant, clinical isolates from patients in a general tertiary care hospital in Athens, Greece. Standard laboratory methods were used for susceptibility testing to commonly used antibiotics and the detection of extended-spectrum-beta-lactamase (ESBL) and metallo-beta-lactamase (MBL) production. The minimum inhibitory concentration (MIC) of fosfomycin for each isolate was determined by the agar dilution method. All K. pneumoniae isolates were both ESBL and MBL producers; all P. aeruginosa isolates were ESBL producers. The K. pneumoniae strains had fosfomycin MICs distributed across a range of 8-64 microg/ml; MIC(50) was 16 microg/ml and MIC(90) 32 microg/ml. The fosfomycin MICs of the P. aeruginosa strains had a distribution across a range of 4 to over 512 microg/ml; MIC(50) was 32 microg/ml and MIC(90) 128 microg/ml. The fosfomycin MICs of the A. baumannii strains had a distribution across a range of 64 to over 512 microg/ml; MIC(50) was 256 microg/ml and MIC(90) more than 512 microg/ml. Although standardized fosfomycin MIC interpretative breakpoints for the species studied are lacking, the findings of our study support the idea that fosfomycin may be further investigated as one among a decreasing list of therapeutic options for the treatment of infections due to multidrug-resistant strains of, primarily, K. pneumoniae and, secondly, P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18214558     DOI: 10.1007/s10096-007-0456-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  28 in total

1.  Microbiological basis for the use of fosfomycin trometamol as single-dose therapy for simple cystitis.

Authors:  M R Gismondo; M A Romeo; A M Lo Bue; G Chisari; G Nicoletti
Journal:  Chemioterapia       Date:  1986-08

2.  Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

Authors:  M Frossard; C Joukhadar; B M Erovic; P Dittrich; P E Mrass; M Van Houte; H Burgmann; A Georgopoulos; M Müller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii.

Authors:  L Martinez-Martinez; G Rodriguez; A Pascual; A I Suárez; E J Perea
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

Review 4.  Fosfomycin trometamol.

Authors:  D S Reeves
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

5.  Interaction of fosfomycin with other antimicrobial agents: in vitro and in vivo studies.

Authors:  T Olay; A Rodríguez; L E Oliver; M V Vicente; M C Quecedo
Journal:  J Antimicrob Chemother       Date:  1978-11       Impact factor: 5.790

6.  [Evolution of antimicrobial susceptibility of Acinetobacter baumannii clinical isolates].

Authors:  S López-Hernández; T Alarcón; M López-Brea
Journal:  Rev Esp Quimioter       Date:  2000-12       Impact factor: 1.553

7.  Beta-lactam-fosfomycin antagonism involving modification of penicillin-binding protein 3 in Pseudomonas aeruginosa.

Authors:  J A Reguera; F Baquero; J Berenguer; M Martinez-Ferrer; J L Martinez
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

8.  Comparative study of fosfomycin activity in Mueller-Hinton media and in tissues.

Authors:  G A Dette; H Knothe; B Schönenbach; G Plage
Journal:  J Antimicrob Chemother       Date:  1983-06       Impact factor: 5.790

9.  An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project.

Authors:  G Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

10.  [Preliminary study of the antagonistic effects between fosfomycin and beta-lactams on Pseudomonas aeruginosa observed on the antibiogram].

Authors:  Y Buisson; R Bercion; P Mauclère; L Hugard; H Schill
Journal:  Pathol Biol (Paris)       Date:  1988-06
View more
  16 in total

Review 1.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

Review 2.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

Review 3.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

4.  Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.

Authors:  A Bruce Montgomery; Paul R Rhomberg; Tammy Abuan; Kathie-Anne Walters; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

5.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

6.  Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.

Authors:  G Samonis; E Koutsounaki; D E Karageorgopoulos; P Mitsikostas; C Kalpadaki; V Bozionelou; I Bompolaki; J Sgouros; V Taktikou; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-31       Impact factor: 3.267

Review 7.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

8.  Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin.

Authors:  Marina Borisova; Jonathan Gisin; Christoph Mayer
Journal:  Microb Drug Resist       Date:  2014-05-12       Impact factor: 3.431

9.  Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.

Authors:  Elizabeth A Neuner; Jennifer Sekeres; Gerri S Hall; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

10.  Susceptibility of urinary tract bacteria to fosfomycin.

Authors:  Sofia Maraki; George Samonis; Petros I Rafailidis; Evridiki K Vouloumanou; Emmanuel Mavromanolakis; Matthew E Falagas
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.